secwatch.observer — SEC 8-K summary
======================================

Issuer:     AGIOS PHARMACEUTICALS, INC. (AGIO)
CIK:        0001439222
Form:       8-K
Filed at:   2022-10-27T23:59:59+00:00
Accession:  0001193125-22-270979
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Agios sells TIBSOVO royalty rights to Sagard for $131.8M upfront
----------------------------------------------------------------

- Upfront cash payment of $131.8M for 5% royalty on U.S. net sales of TIBSOVO (ivosidenib).
- Agios retains $200M milestone for vorasidenib and 15% royalties on its U.S. net sales.
- Deal provides non-dilutive capital to fund PYRUKYND launch and ongoing pipeline programs.
- Transaction closed on October 27, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1439222/000119312522270979/0001193125-22-270979-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1439222/000119312522270979/d409394d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-270979

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer